CJC-1295 No DAC, also known as modified GRF (1-29), is a synthetic 29-amino-acid analog of growth hormone-releasing hormone (GHRH) that carries stabilizing substitutions but omits the Drug Affinity Complex (DAC) used in the longer-acting variant. For research teams studying the somatotropic axis, it offers a shorter-acting GHRH-receptor tool. Puritide Research supplies CJC-1295 No DAC as a high-purity, research-use-only material, synthesized for in vitro and animal-model work and backed by third-party-verified certificates of analysis so your data rests on consistent, documented quality.
Available Sizes
- ›CJC-1295 No DAC 5 mg Vial
- ›CJC-1295 No DAC 10 mg Vial
Product Specifications
- Application
- GHRH-receptor signaling research (short-acting GHRH analog)
- Appearance
- Solid, white lyophilized powder in a sealed glass vial
- Chemical Formula
- C152H252N44O42
- CAS Number
- 863288-34-0
- Molecular Weight
- ~3367.9 g/mol
- Synonyms
- CJC-1295 without DAC, Modified GRF (1-29), Mod GRF 1-29, CJC-1295 DAC-free, tetrasubstituted GRF (1-29)
- Storage
- Store at ≤25°C, sealed, away from heat, light, and moisture. For extended storage, keep lyophilized and refrigerated or frozen.
What Is CJC-1295 No DAC?
CJC-1295 No DAC is a synthetic analog of the first 29 amino acids of growth hormone-releasing hormone (GHRH 1-29), the biologically active fragment of native GHRH. It incorporates several amino acid substitutions relative to the native sequence that are studied for their contribution to resistance against enzymatic cleavage while retaining GHRH-receptor engagement.
Unlike CJC-1295 with DAC, this variant does not carry the Drug Affinity Complex, a maleimide group that binds serum albumin to extend circulating half-life. As a result, the No-DAC form is studied as a shorter-acting GHRH-receptor agonist, making it useful for research into pulsatile signaling and time-resolved receptor pharmacology.
Present understanding derives from in vitro assays, animal models, and human research on related GHRH analogs. Findings should be interpreted within their experimental context and not treated as established clinical outcomes. Puritide Research supplies CJC-1295 No DAC strictly for laboratory use; it is not approved for human or veterinary application.
CJC-1295 No DAC Mechanism of Action (Research Only)
CJC-1295 No DAC is studied as a GHRH-receptor agonist used to investigate signaling in somatotroph cells. The mechanisms below reflect observations from biochemical assays, cell-culture studies, and animal models, and should be read strictly in a research context.
GHRH-Receptor Engagement
As an analog of GHRH (1-29), CJC-1295 No DAC is investigated for its interaction with the GHRH receptor on pituitary somatotroph cells. In experimental systems, receptor engagement is associated with cAMP-dependent signaling and the initiation of pulsatile growth hormone release, providing a model for studying the somatotropic axis.
Structural Stability & Short Duration
The substitutions distinguishing modified GRF (1-29) from native GHRH are studied for their role in reducing susceptibility to dipeptidyl-peptidase cleavage, extending in vitro stability relative to the native peptide. Because this variant lacks the albumin-binding DAC group, its circulating persistence is short compared with the DAC form.
This shorter duration is a deliberate research feature: investigators use CJC-1295 No DAC to examine time-resolved and pulsatile receptor signaling, and to compare short-acting versus long-acting GHRH analogs within the same experimental framework.
CJC-1295 No DAC Research Applications
CJC-1295 No DAC is investigated across preclinical studies as a GHRH-receptor tool for exploring somatotropic-axis signaling. The observations below derive from biochemical studies, cell-based assays, and animal models, and should be interpreted within their respective settings.
GHRH Pharmacology & Pulsatile Signaling
A primary application is investigating GHRH-receptor engagement and the resulting pulsatile signaling dynamics in somatotroph-model systems. Its short duration makes it useful for studies that require time-resolved stimulation rather than sustained receptor occupancy.
The peptide is also frequently paired with GHS-receptor agonists such as Ipamorelin in convergent-signaling research, where investigators study how distinct receptor pathways interact within the same model.
Comparative & Endocrine Models
Researchers use CJC-1295 No DAC in comparative studies contrasting short-acting and DAC-modified GHRH analogs, characterizing differences in signaling duration and stability. These studies aim to improve understanding of GHRH-receptor pharmacology rather than to establish physiological or therapeutic effects.
Comparison
| Parameter | CJC-1295 No DAC | CJC-1295 With DAC | Ipamorelin |
|---|
| Molecular classification | GHRH (1-29) analog | GHRH (1-29) analog with DAC | Synthetic pentapeptide GHS |
| Primary receptor target | GHRH receptor | GHRH receptor | Ghrelin / GHS receptor |
| Albumin-binding DAC group | Absent | Present | Absent |
| Studied duration profile | Short-acting | Long-acting | Short-acting |
| Primary research focus | Pulsatile GHRH signaling | Sustained GHRH signaling | Selective GHS signaling |
Laboratory Safety & Handling (Research Use Only)
CJC-1295 No DAC is a synthetic, lyophilized research peptide for laboratory investigation only. It should be handled by qualified personnel in controlled environments, in accordance with institutional policies, laboratory safety procedures, and applicable regulations. As a research material, laboratories should implement practices that prioritize material integrity, traceability, and reproducibility.
Handling & Storage Guidelines
Follow institutional SOPs, chemical hygiene plans, and approved protocols; wear appropriate PPE (lab coat, gloves, eye protection); and use engineering controls where required. Record lot numbers, storage conditions, and handling activities, and retain Certificates of Analysis and batch documentation to support traceability and audit readiness.
Store material under the conditions specified in product documentation, protected from excessive heat, moisture, and direct light. Reconstituted peptide should be kept refrigerated and used within the timeframe indicated by your protocol. Consistent handling and documentation support reliable, reproducible outcomes.
Certificate of Analysis & Quality Assurance
Each CJC-1295 No DAC batch ships with a third-party-verified Certificate of Analysis, providing transparent, research-grade quality control. The CoA includes a purity assessment (HPLC / reverse-phase chromatography), mass-spectrometry identity confirmation, and lot number, testing date, and method documentation.
Researchers may request sample CoAs (PDF) ahead of purchase to confirm testing parameters, analytical methods, and batch consistency, and are encouraged to perform independent verification.
Research Use Only
